CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

PURPOSE: CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lancet, Jeffrey E., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Hoering, Antje, Banerjee, Kamalika, Chiarella, Michael, Louie, Arthur C., Medeiros, Bruno C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
RAPID COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025/
https://www.ncbi.nlm.nih.gov/pubmed/30024784
http://dx.doi.org/10.1200/JCO.2017.77.6112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025/
https://www.ncbi.nlm.nih.gov/pubmed/30024784
http://dx.doi.org/10.1200/JCO.2017.77.6112

Ejemplares similares